[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559447":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":31,"locations":38,"responsibleParty":53,"collaborators":36,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":36,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":36,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":41,"whyStopped":36,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vonoprazan 20mg (Vonseca)","ACTIVE_COMPARATOR","• Group 1 (control group): 22 patients who will receive Vonoprazan 20mg (Vonseca) and placebo of pantoprazole (pantoloc) daily for 8 weeks",[13],"Drug: Vonoprazan 20 mg versus Pantoprazole 40 mg",{"label":15,"type":10,"description":16,"interventionNames":17},"Pantoprazole 40 mg (Pantoloc)","• Group 2: 22 patients who will receive Pantoprazole 40 mg (Pantoloc) and placebo of vonoprazan (vonseca) daily for 8 weeks.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Vonoprazan 20 mg versus Pantoprazole 40 mg","Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole",[15,9],[25],"Vononoprazan (Vonesca) versus pantoprazole (pantoloc)",[27],{"name":28,"affiliation":29,"role":30},"Aya Hany Abdel Aziz","Master degree student at faculty of pharmacy - Tanta university","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Aya Hany Abdel Aziz, Bachelor","CONTACT","+201144818823",null,"PG_172956@pharm.tanta.edu.eg",[39],{"facility":40,"status":41,"city":42,"state":36,"zip":36,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Theodore Billiharz Institute for Researchs","RECRUITING","Giza","Egypt","EG",{"type":46,"coordinates":47},"Point",[48,49],31.20861,30.00944,{"lat":49,"lon":48},[52],{"name":33,"role":30,"phone":36,"phoneExt":36,"email":36},{"type":30,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"Aya Hany Abdelaziz Fahmy","Master degree student at faculty of pharmacy","100559447","phase-4-clinical-study-evaluating-the-role-of-vonoprazan-versus-pantoprazole-in-patients-with-gastroesophageal-reflux-disease-100559447",false,"NCT06564246","Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* Age 17-60 years.\n* Both genders.\n* Patients with a score ≥ 8 on the Gastroesophageal Reflux Disease Questionnaire (Gerd Q) are defined as having GERD and will enroll in this study and it will be done at baseline and after 8 weeks.\n\nExclusion Criteria:\n\n* Subjects with history of gastrointestinal disease, gastroduodenal surgery, inflammatory bowel disease and Barrett's esophagus.\n* Subjects with an earlier or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders (gastric or duodenal ulcer).\n* Subjects with history of total\u002Fsubtotal gastrectomy and esophageal achalasia.\n* Subjects with Corona virus disease (COVID19).\n* Subjects with major cardiological, respiratory, endocrine metabolic disease and neuro-psychological disease.\n* Pregnancy or lactation.\n* Subjects with total bilirubin level ≥ 1.2 mg\u002Fdl and ALT level \\> 100 IU\u002Fl.\n* Subjects with renal impairment (Crcl less than 30 ml\u002Fmin).\n* Patients receiving atazanavir sulphate, nelfinavir and rilpivirine hydrochloride due to potential drug interactions.","ALL","17 Years","60 Years",{"count":66,"type":67},44,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","This study aims to investigate the possible efficacy of vonoprazan versus Pantoprazole in patients with gastroesophageal reflux disease.",[73],"Gastroesophageal Reflux Disease (GERD)",[75,76,73,77,78],"Vonoprazan","Pantoprazole","Gastrin serum level","E-Cadherin level","2024-12-04",{"date":81,"type":82},"2024-12-05","ACTUAL",{"date":84,"type":82},"2024-09-18",{"date":86,"type":67},"2026-10",{"name":5,"class":6},1]